TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice. TARGET-NASH is a research registry of patients with NAFL or NASH within academic and community real-world practices maintained in order to assess the safety and effectiveness of current and future therapies.
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
-
Banner University Medical Center - Phoenix Transplant Center and Advanced Liver Clinic, Phoenix, Arizona, United States, 85006
Stanford University, Palo Alto, California, United States, 94304
California Liver Research Institute, Pasadena, California, United States, 91105
University of California, Davis, Sacramento, California, United States, 95817
Silicon Valley Research Institute, San Jose, California, United States, 95128
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States, 80045
Connecticut Gastroenterology, Hartford, Connecticut, United States, 06105
Connecticut Children's Medical Center, Hartford, Connecticut, United States, 06106
Medstar Georgetown Transplant Institute, Washington, District of Columbia, United States, 20007
Gastro Florida, Clearwater, Florida, United States, 33762
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
2 Years to
ALL
No
Target PharmaSolutions, Inc.,
2036-07